RRAS2 and B-cell chronic lymphocytic leukemia: Interestingly, the comparison of RRAS2 mRNA expression established by RT-qPCR of the 178 samples from non-treated CLL patients with that of the 14 Ibrutinib-treated patients of the new 51 patient cohort, showed a significant reduction in RRAS2 expression in treated patients (Figure 4a).